KR20130083692A - Beverage composition for improving menopausal symptoms comprising fermented soybean hypocotyl and prepration method of the same - Google Patents

Abstract

PURPOSE: A producing method of a beverage composition for reducing climacteric symptoms containing a soybean gemmule fermented product is provided to ferment soybean gemmule using a specific bifidobacterium strains. CONSTITUTION: Bifidobacterium lactis BL740 strains are inoculated into a mixture of 8-10 parts by weight of pulverized soybean gemmule and 100 parts by weight of water for fermenting at 35-37°C for 45-50 hours, and the mixture is freeze-dried to obtain a soybean gemmule fermented product. The soybean gemmule fermented product is mixed with a soybean extract, soymilk, a soybean lecithin, maltodextrine, white sugar, a vitamin source, and an inorganic source. A beverage composition for reducing climacteric symptoms contains more than 25 mg/per 1 can of isoflavone in an aglycon form.

Description

Beverage composition for improving Menopausal Symptoms comprising Fermented Soybean Hypocotyl and prepration method of the same}

The present invention relates to a beverage composition and a method for producing the same, which are effective for improving menopausal symptoms, including soybean embryo fermented by fermenting soybean embryo using a specific Bifidobacterium strain.

The content of isoflavones in soybeans varies according to varieties and parts, but is generally present in glycosides in the amount of 0.1-0.6%. In particular, the content of daidzin and genistin accounts for 60 ~ 70%, while the content of non-glycoside forms of daidzein and genistein is about 0.01 ~ 0.15%, which is relatively small amount [Wang HJ, Murphy PA (1994a) J Agric Food Chem 42, 1666-1673; Wang HJ, Murphy PA (1994b) J Agric Food Chem , 42 , 1674-1677] soybean embryos have been reported to have a content of 1.0-1.5%, 10 times higher than cotyledons [Schryver T (2002) Cereal Foods World 47 , 185-188.

Soy isoflavone is known to act as an antagonist or agonist of female hormone estrogen by binding to estrogen receptor due to its structural similarity with estrogen. Kris-Etherton PM, et al. (2002) Am J Med 30 , 71-88.

Studies on the improvement effect of isoflavones on facial flushing in postmenopausal women have been actively conducted and reported to have a positive effect. [Augusto Feraari, (2009) J Obstet Gynaecol Res 35, 1083-1090; Nahas EAP, et al. (2007) Maturitas 58, 249-258; Faure ED, et al. (2002) Maturitas 53, 49-58; Murkies AL, etc. (1995) Maturitas 21, 189-195]

In addition to improving menopausal symptoms and osteoporosis in women [Arjmandi BH, et al. (2002) J Nutr Biochem 13 , 130-137; Harkness LS, et al (2004) J Womens Health 13 , 1000-1007], as well as anticancer effects [Constantinou AI, et al. (1996) Anticancer Res 16 , 3293-3298] prevention of atherosclerosis [Clarkson TB (2002) J Nutr 132 , 566S-569S]. Reported.

In this way, isoflavone intake in soybean or soybean embryo can be expected to have various functional effects such as menopausal symptoms, osteoporosis improvement, arteriosclerosis prevention, and anticancer effect, but glycoform isoflavones present in soybean or soybean embryos It has been reported that bioavailability is relatively lower than glycoside forms [Izumi T, et al. (2000) J Nutr 130, 1695-1699; Setchell KDR, et al. (2001) J Nutr 131, 1362S-1375S; Zubik L, Meydani M (2003) Am J Clin Nutr 77, 1459-1465. In general, glycoside isoflavone absorption should be preceded by conversion to nonglycosides through intestinal flora. Therefore, it takes a lot of time to move to the large intestine and convert non-glycosides by intestinal flora (Kuhnau et al., 1976 World). Rev Nutr Diet 24 , 117-91. It is also reported that glycoside isoflavones have higher solubility than nonglycosides, but isoflavones are absorbed by the nonionic passive diffusion mechanism, which suggests that the nonglycoside forms favor this absorption mechanism [Setchell et al ., 2002 Am J Clin Nutr 76, 447-453.

Therefore, the physiological functionality of isoflavones can be enhanced when bioconversion to non-glycosides, and soybean embryos containing the most isoflavones are mostly removed and discarded in the soybean processing process. It is very important. Isoflavone glycosides are metabolized to beta-glycosides by beta-glucosidase, and related techniques include the production of non-glycosides through enzyme treatment and Bifidobacterium. Biotransformation techniques using strains have been reported. Matsura M, et al. (1989) J Food Sci 54 , 5677-5679; Matsuura M, et al. (1993) J Food Sci 58 , 144-147]

Related Korean Patent Registration No. 100989174, 'Yeast hydrolyzate having an effect on improving women's menopausal symptoms and food comprising the same' is a composition for preventing and improving menopausal or menopausal disorders, including the yeast hydrolyzate, and the It relates to a method for preparing the composition, which is said to be effective for various symptoms and diseases caused by menopause such as osteoporosis, depression, decreased sex hormones, decreased ovarian function, such as normalizing blood hormones and improving bone tissue.

As a related prior patent, Korean Patent Publication No. 1020050052451, 'Manufacturing method of health functional food containing phytoestrogens derived from pomegranate' is catechin 1.0 ~ 2.0ppm, dyedzein 20 ~ 30ppm, genistein 0.1 ~ 0.5ppm, quercetin Menopausal or postmenopausal women comprising from 0.1 to 99% by weight of pomegranate extract, comprising 8.0 to 14.0 ppm, 0.05 to 0.3 ppm of 17β-estradiol, and 0.01 to 0.10 ppm of 2,3-di-MeO-estradiol Provided is a method for preparing a phytoestrogens-containing health functional food for the prevention of osteoporosis or hot flashes, and since the functional food prepared by the method contains a large amount of safe phytoestrogens with excellent estrogen properties and no side effects, menopause Or be able to effectively prevent and treat any symptoms that may be caused by estrogen deficiency in postmenopausal women. Is expected to be particularly prominent, indicating the effect on hot flashes, osteoporosis, heart disease, atheromatous degree, body fat increased symptoms as side effects is very low base.

The present invention has been made by the above necessity, an object of the present invention is to provide a composition for improving menopausal symptoms comprising soybean embryo fermentation.

Another object of the present invention is to provide the above production method.

In order to achieve the above object, the present invention is fermented by adding Bifidobacterium lactis BL740 to soybean embryos and dried to obtain a soybean embryo fermentation, soybean embryo fermented product soybean extract, soybean oil, soybean lecithin, maltodextrin, white sugar, It provides a beverage composition for improving menopausal symptoms comprising the step of mixing with vitamins and minerals.

In one embodiment of the present invention, the soybean embryo fermentation is preferably 0.5 to 1.0 parts by weight in the total composition, but is not limited thereto.

In another embodiment of the present invention, the soybean embryo fermentation is obtained in the mixture of 8-10 parts by weight of soybean germ crushed, 100 parts by weight of water Bifidobacterium lactis It is preferable to add the BL740 strain and then fermented at 35 to 37 ° C. for 45 to 50 hours, followed by lyophilization, but is not limited thereto.

In another aspect, the present invention provides a beverage composition for improving menopausal symptoms produced by the method of the present invention.

The present invention provides the following means for solving the above problems. In one embodiment of the present invention, the Bifidobacterium strain is preferably B. lactis BL740 of Christian Hansen, but is not limited thereto.

In one embodiment of the invention, soybean embryos are ground finely to about 100 to 300 mesh and then sterilized at 121 to 122 ° C. for 25 to 30 minutes.

In one embodiment of the present invention, the Bifidobacterium strain is added to a mixture of 8-10 parts by weight of sterile soybean embryo pulverized and 100 parts by weight of water and fermented at 35 to 37 ° C. for 45 to 50 hours to ferment the soybean embryo fermentation broth. Get

In one embodiment of the invention, the soybean embryo fermentation broth is dried for 48 to 72 hours using a lyophilizer to obtain soybean fermentation.

In one embodiment of the invention, 0.5-1.0 parts by weight of soybean embryo fermentation is mixed with 50-80 g of soy extract, purified water, soybean oil, soy lecithin, maltodextrin, white sugar, vitamin source and mineral source to produce a beverage mixture.

In one embodiment of the present invention, the beverage mixture is filtered and then sterilized for 48 to 72 seconds at 120 to 135 ° C. through homogenization. Once sterilization is complete, the cans are filled and seamed through secondary filtration. The seamed cans are transferred to a retort facility and sterilized at 122-125 ° C. for 10-11 minutes.

The above-mentioned manufacturing method relates to a beverage composition for menopause improvement, including soybean extract, soybean embryo fermentation.

As can be seen through the present invention, the present invention has an effect on the weight, biochemical changes, bone density, bone minerals in the femur, bone minerals and Dpd in the urine, blood hormones and bone metabolism and cytokine concentration in the ovarian resection model Experimental results can provide a beverage composition containing soybean embryo fermentation showed a significant effect in all indicators and the beverage composition provided in the present invention can be expected to improve the health of menopausal women.

1 is a process diagram illustrating a beverage manufacturing method for improving menopausal symptoms according to an embodiment of the present invention.
Figure 2 is the result of examining the effect of soybean fermentation on the change in body weight in the effect of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention more specifically, and the scope of the present invention is not limited by these examples in accordance with the gist of the present invention.

Example  One: Bifidobacterium  Preparation of spawn

The strain used in the present invention was supplied by Christian Hansen B. lactis BL740 from Samik Dairy Co., Ltd. and the strain was stored frozen at -65 ℃ or less. The initial growth of the strain was inoculated in 200 mL of Lactobacilli MRS broth (Difco Laboratories, Detroit, MI, USA) medium and incubated at 37 ° C. for 24 hours to prepare a culture medium, and then inoculated in 2 L of Lactobacilli MRS broth medium again at 37 ° C. Incubated for 24 hours at to obtain a final culture.

Example  2: Soybean embryo Fermented  Produce

Soybean embryos were supplied from regular food and used to prepare soybean germ fermented products. Soybean embryos were ground using a crusher and sterilized at 121 ° C. for 30 minutes. 16 kg of sterile soybean pulverized powder was placed in a fermenter of 500 L volume and 200 L of water and 2 L of spawn culture were added to ferment for 46 to 50 hours at 37 ° C. The fermentation period was stirred at a speed of 10 rpm to increase the fermentation efficiency.

The fermented broth was fermented after 72 hours using a freeze dryer to obtain fermented soybean embryos.

Example  3: Formulation of beverage composition and beverage production

Soybean extract 75.05g, maltodextrin 11.74g, soybean germ 0.7g, fructose 2g, sodium caseinate 0.45g, soybean oil 0.52g, soy lecithin 0.2g, choline chloride 0.033g, indigestible maltose Dextrin 0.55g, Powdered Vitamin A 1.259mg, Vitamin B1 Hydrochloride 0.158mg, Vitamin B2 0.165mg, Vitamin B6 Hydrochloride 0.173mg, Vitamin B12 0.59µg, Vitamin C 23.253mg, Vitamin D3 0.307mg, Vitamin E Acetate 2.579mg, Vitamin K1 0.18 mg, folic acid 0.055 mg, nicotinic acid amide 1.728 mg, biotin 5.6 μg, pantothenate calcium 0.701 mg, calcium carbonate 0.0682 g, liquid calcium carbonate 0.55 g, calcium phosphate 0.112 g, potassium citrate 0.1365 g, zinc oxide 1.3 mg, sulfuric acid Ferrous iron 6.5mg, magnesium chloride 0.15g, copper sulfate 0.3mg, manganese sulfate 0.9mg, dry yeast (Se) 2.33mg, dry yeast (Mo) 0.59mg, dry yeast (Cr) 1.17mg, savory flavor 0.15g, gellan gum 0.01 g is mixed with 100 parts of purified water to prepare a beverage for menopause improvement. The.

Example  4: filtration, homogenization, sterilization of blended beverages and Filling

The blended composition was filtered and then sterilized for 72 seconds at 135 ° C. through homogenization. After sterilization was completed, seam was filled by filling the cans after the second filtration. The seamed cans were sterilized at 122 ° C. for 10 minutes using a retort facility to prepare drinks for menopause improvement.

Experimental Example  1. Preparation of feed

Table 1 is related to feed composition, soybean embryos 23g / kg, soybean embryo fermentation 30g / kg and EQUOL 31.2g / kg, respectively, were added to the basic composition of the AIN-93M diet. It was paid. In the case of the normal control group and the sham group, the basic composition of the AIN-93M diet was supplied.

Furtherance Normal diet SEE
(23 g / kg) SEF
(30 g / kg) EQUOL
(31.2 g / kg) Casein 140 140 140 140 L-Cystine 1.8 1.8 1.8 1.8 Sucrose 100 100 100 100 Cornstarch 465.692 465.12 465.12 465.12 Dyetrose 155 155 155 155 Soybean oil 40 40 40 40 t-Butylhydroquinone 0.008 0.008 0.008 0.008 Cellulose 50 50 50 50 Mineral Mix # 210050 35 35 35 35 Vitamin mix # 310025 10 10 10 10 Choline bitartrate 2.5 2.5 2.5 2.5 Soybean Extract 10 23 30 31.2 Gross energy content
(kcal / g) 1000 3519.1912 3493.9912 3489.6712

Table 1 shows the feed composition table. In the table

* AIN mineral mixture (g / kg): calcium phosphate dibasic 500, sodium chloride 74, potassium citrate 220, potassium sulfate 52, magnesium oxide 24, manganous carbonate 3,5, ferric citrate 6, zinc carbonate 1,6, cupric carbonate 0.3 , potassium iodate 0.01, sodium selenate 0.01, chrominium potassium sulfate 0.55.

AIN vitamin mixture (g / kg): thiamine HCl 0.6, rivoflavin 0.6, pyridoxine HCl 0.7, niacin 3, calcium pantothenate 1.6, folic acid 0.2, biotin 0.02, vitamin B12 (0.1% trituration in mannitol) 1, dry vitamin A palmitate ( 500,000 U / g) 0.8 dry vitamin E acetate (500 U / g) 10, vitamin D, trituration (400,000 U / g), 0.25, manadione sodium bisulfate complex 0.15.

Experimental Example  2. Effect on weight change

Due to the effect of soybean fermentation on the change of body weight in the effects of the present invention, the weight of all animals was measured once before the start of administration, twice a week after the start of administration, and on the day of necropsy. The effect on body weight was significantly increased in the ovarian ablation group (p <0.01) compared to the normal control group and the sham group, and the change was significantly increased in the soybean embryo fermentation group and the fermentation microorganism group. There was a trend but no statistical significance was observed (FIG. 2).

Experimental Example  3. Effects on Biochemical Changes

Table 2 shows the results of experiments on the effects of soybean fermentation on biochemical changes in the effect of the present invention. Blood biochemical tests were performed on animals fasted 20 to 24 hours before autopsy under ether anesthesia, and the blood obtained from pre-bleeding blood from the abdominal vein was placed in a serum separation centrifuge tube (SST-tube, BD vaccutainer, USA) for 30 minutes at room temperature. After standing and coagulating, serum obtained by centrifugation (3,000 rpm X 15 min) was tested for biochemical tests including alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol, and triglycerides. Hitachi Medical, Co., LTD., Japan), and all experimental procedures and test methods were tested according to the clinicopathological method. In the main biochemical indicators, calcium and phosphorus were significantly decreased in ovarian ablation group compared with normal and sham group, while calcium and phosphorus absorption were significantly increased in test substance including normal group, especially soybean embryo and soybean fermented fertilizer. Was significantly inhibited. These results suggest that ovarian resection caused the loss of minerals in the blood, which supports the results in the femur and urine.

       After 12 weeks, serum glucose levels were significantly increased in the ovarian resection group (P <0.01) compared to the normal group and the Sham group. The soybean embryo extract and Equal-treated group showed a tendency to be suppressed compared to the ovarian ablation group, but no statistical significance was observed. On the other hand, the soybean embryo fermentation group was significantly inhibited compared to the ovarian ablation group (P <0.01). The activity of alkaline phosphatase was significantly increased in the OVX group at 74.2 ± 3.6 IU / L compared to the normal group (p <0.05). On the other hand, soybean embryo extract, soybean embryo fermentation and equal treatment showed inhibition of ALP activity compared to OVX group, but there was no significant difference. ALP is an important indicator of osteoblastic activity and is present in osteoblasts and increases in blood levels as bone formation progresses actively. After menopause, osteoporosis, fracture patients and early stages of growth and Ca deficiency have been reported. have. In another previous study, Sprague-Dawley female rats reported higher levels of ALP in the ovarian resection group than the laparotomy group. In the present study, the serum ALP concentration was increased in the ovarian resection group compared to the normal group, and the increase in ALP was suppressed in the soybean embryo-related group.

       The AST and ALT indices of liver function were significantly increased in the ovarian ablation group compared to the normal control group, whereas the AST was significantly increased in the Sham group compared to the normal group (P <0.05 ~ 0.01). On the other hand, both AST and ALT were significantly reduced in all test substance-treated groups and returned to normal levels. However, soybean embryo fermentation tended to decrease in both AST and ALT compared to normal control. These results suggest that soybean embryos or fermented products play an important role in the normal recovery of the reduced liver function caused by ovarian ablation.

       In lipid-related indicators, total cholesterol, low-density cholesterol, and triglycerides were significantly increased due to ovarian ablation compared to the normal control group (P <0.05). On the other hand, the soybean embryo extract group, which was treated with the test substance, showed a significant decrease in the neutral lipid, and the soybean fermented group showed a significant decrease in the total cholesterol and low density ALAC. On the other hand, no changes were observed in all of the lipid-related indicators in the equal group. Ovariectomy significantly increased blood glucose levels, high cholesterol, low density cholesterol and triglycerides. The increase in glucose and lipids due to ovarian ablation is reported in several other papers, which is consistent with the results of this study. In particular, the fermented soybean embryos in this test substance were significantly inhibited in both sugar and lipid indices, and thus, further study is required for fragrant sugar and lipids.

Table 2 shows the effects of soybean fermentation on blood biochemical changes.

Experimental Example  4. Effect on Bone Mineral Density

       Bone density, embryo fermentation extract, and fermented bacteria were administered daily to the ovarian excised rats for 12 weeks, and bone mineral density was measured in each group. As a result, it was confirmed that the BMD of the ovarian ablation group, the soybean embryo extract, and the equal administration group were significantly decreased compared to the normal group. On the other hand, it was observed that the test material administration group, that is, soybean embryo administration group, soybean embryo fermentation administration group and Equal administration group, increased significantly compared to the ovarian resection group (P <0.05 ~ 0.01). Soybean embryo extract, soybean embryo fermentation and equal administration of the present invention showed a tendency to improve bone density, especially in the group administered soybean fermented product, so that soybean fermented product in ovarian ablation It is thought to be an effective substance to prevent osteoporosis that occurs frequently in postmenopausal women by preventing bone loss.

Table 3 shows the effects of soybean fermentation on osteoporosis changes.

Experimental Example  5. femur Ash content  And impact on the change of minerals

The ash content in the femur was significantly decreased in the OVX group to 402 ± 0.2 mg compared to the normal group (p <0.05). On the other hand, the soybean germ extract, soybean germ fermentation and equal administration group increased significantly compared to the ovarian ablation group (p <0.05). The calcium and ash content of the femur is shown in Table 4. The calcium content in the femur was significantly decreased in the ovarian ablation group to 117 ± 11.2 mg compared with the normal group (p <0.05). On the other hand, the SEE and SEF groups fed with soybean embryo extract and soybean embryo fermentation, respectively, added to the basic diet without calcium, which was significantly increased compared with ovarian resection group (131 ± 10.5 mg and 129 ± 21.3 mg). 0.05). Meanwhile, the phosphorus content in the femur was also the same as the calcium content. No significant change was observed in the equal group.

Table 4 is a table showing the effect of soybean fermentation on bone mineral in the femur. Experimental Example 6. Effect on urinary bone mineral and Dpd

In the effect of soybean fermentation on urinary bone minerals and Dpd, calcium content in urine increased significantly compared to normal control and sham groups, whereas the control group was significantly suppressed in both groups. Seemed. On the other hand, the phosphorus content in urine was significantly increased in the ovarian ablation group, while the test substance-treated group was significantly inhibited only in the soybean fermented group. Meanwhile, the effect on urinary deoxypyridinoline (Dpd) was significantly increased in ovarian resection group and microorganism administration group compared with sham group including normal control group, whereas it was suppressed in soybean and soybean embryo fermentation group compared with ovarian resection group. There was a tendency to decrease in Equal-treated group but statistical significance was not recognized.

Table 5 shows the effect of soybean fermentation on bone minerals and Dpd in the urine.

Experimental Example  7. With hormones in the blood Metabolism  Impact

In the effects of soybean fermentation on blood hormone and bone metabolism indices, hormones Estradiol and LH were measured using the radioisotope RIA (RAIDUM, France) using a rat-specific monoclonal antibody, and Osteocalcin was used in the rat-specific Osteocalcin ELISA kit ( Biomedical Technologies Inc., USA) was used to analyze the ELISA reader. Estradiol is a major estrogenic hormone, the most active form of estrogen. Estradiol measurement is one of the most important indicators for diagnosing pubertal delay, amenorrhea and menopause. In addition, decreased estradiol and estrogen are known to increase bone resorption and decrease calcium absorption in the digestive tract, which is associated with postmenopausal osteoporosis. In the present invention, the embryo extract, the embryo fermentation and the equal group showed a tendency to decrease in all groups including the ovarian ablation group compared to the normal control group, but the statistical significance was not observed, but it was significantly increased in all the test substance administration groups compared to the ovarian ablation group. (p <0.01). Meanwhile, after 12 weeks of daily administration of soybean embryo extract, soybean embryo fermentation, and equal to the ovarian excised rats, the osteocalcin content in serum of each group is shown in Table 6. The serum osteocalcin content was 40.17 ± 5.23 ng / mL in the ovarian resection group (p <0.01), while that of the embryo embryo extract group was 30.4 ± 3.24 ng / mL and soybean embryo fermentation group. 28.7 ± 1.89 ng / mL and the Equal group showed 33.7 ± 2.71 ng / mL, which showed a significant decrease (p <0.05) in the soybean embryo fermentation group compared to the OVX group, while decreasing tendency was observed in the other groups. No significant significance was observed. On the other hand, no changes were observed in luteinizing hormone in both the ovary ablation group including sham, the fermentation product including soybean embryos, and the bacterial administration group. . There was a tendency to increase in ovarian resection group, but no statistically significant difference was observed.

       Osteocalcin, an indicator of bone formation, is specifically distributed only in bone and dentin. It is also called bone gla protein (BGP), and is a vitamin K-dependent a-carboxy glutamic acid protein that binds to calcium. 70% is accumulated in the bone matrix and 30% is secreted into the blood, which is used as a biochemical index to predict the degree of bone formation. Osteocalcin increases during menopause and decreases after estrogen treatment, which has a significant correlation with changes in bone mineral density and bone biopsy. According to previous studies, increased osteocalcin concentration in younger age means increased bone formation, but it is used as a good predictor of bone loss after menopause. The osteocalcin concentration in the ovarian-resected OVX group of the present invention was increased and significantly decreased in the soybean embryo extract and fermented group compared to the OVX group, so that isoflavones contained in soybean embryos decreased bone replacement rate. Inhibition of absorption seems to have a bone protective effect. In addition, NTx, a widely used index in the bone metabolism index, was significantly increased in the ovarian resection group compared to the normal control group and the sham group, while the test substance administration group was significantly suppressed (P <0.05 ~ 0.01) compared with the ovarian resection group. . CTx decreased in all test groups, including ovarian ablation group, as in NTx, but statistical significance was observed only in ovarian ablation group. In contrast, the soybean fermented group was significantly increased in the test substance-treated group compared with the ovarian ablation group. Serum CTx is a metabolite of osteoclasts mediated by cathepsin K, a type I collagen degrading enzyme during bone lysis.

Table 6 shows the effects of soybean fermentation on blood hormones and bone metabolism.

Experimental Example  8. Effects on Cytokines

The effect of soybean fermentation on cytokines showed that IL-6 was decreased in ovarian ablation group compared to normal group and sham group. TNF-a was significantly increased in ovarian resection group compared with normal group and sham group, whereas test group treatment group was significantly inhibited in both groups. These results showed that soybean embryos or fermented products significantly inhibited the increase of cytokines by ovarian ablation.

Table 7 shows the effect of soybean fermentation on the concentration of cytokines.

Claims (4)

Bifidobacterium in Soybean Embryo lactis Fermentation and drying to add BL740 to obtain soybean embryo fermentation, improving the menopausal symptoms comprising mixing soybean fermentation with soybean extract, soybean oil, soybean lecithin, maltodextrin, white sugar, vitamin source and mineral source Method for producing a beverage composition. The method of claim 1, wherein the soybean embryo fermented product is added to contain at least 25 mg / 1 can of isoflavone in the form of a non-glycoside. The method of claim 1, wherein the soybean germ fermentation is obtained in the Bifidobacterium in a mixture of 8-10 parts by weight of soybean germ powder, 100 parts by weight of water lactis Method for producing a beverage composition for improving menopausal symptoms, characterized in that the fermentation at 35 to 37 ℃ for 45 to 50 hours by the addition of the BL740 strain obtained through lyophilization. A beverage composition for improving menopausal symptoms prepared by the method of any one of claims 1 to 3.

Images